International Assets Investment Management LLC Buys 17,082 Shares of Personalis, Inc. (NASDAQ:PSNL)

International Assets Investment Management LLC lifted its stake in shares of Personalis, Inc. (NASDAQ:PSNL) by 438.0% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 20,982 shares of the company’s stock after acquiring an additional 17,082 shares during the period. International Assets Investment Management LLC’s holdings in Personalis were worth $113,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. nVerses Capital LLC acquired a new position in shares of Personalis during the third quarter valued at about $40,000. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its stake in Personalis by 42.5% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock worth $81,000 after buying an additional 4,504 shares during the period. Public Employees Retirement System of Ohio bought a new position in Personalis in the first quarter worth approximately $29,000. Virtu Financial LLC bought a new position in Personalis in the first quarter worth approximately $41,000. Finally, Price T Rowe Associates Inc. MD grew its stake in Personalis by 58.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 95,000 shares of the company’s stock valued at $142,000 after acquiring an additional 34,900 shares during the period. 61.91% of the stock is owned by institutional investors.

Personalis Stock Down 22.6 %

Shares of NASDAQ:PSNL opened at $4.32 on Friday. The stock has a market cap of $229.31 million, a price-to-earnings ratio of -2.63 and a beta of 1.94. The business’s 50 day moving average is $5.15 and its 200 day moving average is $3.32. Personalis, Inc. has a 12-month low of $0.89 and a 12-month high of $7.20.

Personalis (NASDAQ:PSNL) last released its earnings results on Wednesday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.10. The company had revenue of $22.58 million during the quarter, compared to analyst estimates of $19.81 million. Personalis had a negative return on equity of 56.87% and a negative net margin of 101.78%. During the same period in the prior year, the company posted ($0.50) earnings per share. As a group, equities research analysts expect that Personalis, Inc. will post -1.15 earnings per share for the current year.

Analysts Set New Price Targets

PSNL has been the topic of a number of recent research reports. HC Wainwright increased their target price on Personalis from $7.50 to $9.00 and gave the stock a “buy” rating in a report on Monday, August 19th. Needham & Company LLC reaffirmed a “buy” rating and issued a $7.25 price objective on shares of Personalis in a research note on Thursday. Finally, BTIG Research boosted their target price on shares of Personalis from $5.50 to $7.00 and gave the stock a “buy” rating in a research report on Friday, August 16th.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.